NewAmsterdam is developing obicetrapib, an oral, low-dose, once-daily, and highly selective cholesteryl ester transfer protein (“CETP”) inhibitor, alone or as a fixed-dose combination with ...

After hours: February 6 at 6:44:05 p.m. EST ...

By combining experimental techniques with computer simulations, the FAU team has laid the foundation for developing better fluorescent cholesteryl probes that can be used to study a wide range of ...

NewAmsterdam is developing obicetrapib, an oral, low-dose, once-daily, and highly selective cholesteryl ester transfer protein inhibitor, alone or as a fixed-dose combination with ezetimibe ...

Trabecular meshwork (TM) tissue is subjected to constant mechanical stress due to the ocular pulse created by the cardiac cycle. This brings about alterations in the membrane lipids and associated ...

Department of Radiology, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210008, China ...

HB Wealth Management LLC bought a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) during the 4th ...